Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 33, 601-605, March 1, 1973]
© 1973 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drewinko, B.
Right arrow Articles by Trujillo, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drewinko, B.
Right arrow Articles by Trujillo, J. M.

Demonstration of Common Sarcoma-associated Antigen(s) in an Established Human Neurogenic Sarcoma Cell Line1

Benjamin Drewinko, Charles T. Montgomery and Jose M. Trujillo

Department of Clinical Pathology, The University of Texas at Houston, M. D. Anderson Hospital and Tumor Institute, Houston, Texas 77025

An established human neurogenic sarcoma cell line presented a tumor-associated antigen common to various sarcoma tumors. The antigen was detected by immunofluorescent techniques with the use of the sera of patients bearing such tumors and is located mainly on the cellular surface. The tumor-specific antibody of most sera showed only membrane immunofluorescence while five sera revealed both intracytoplasmic and membrane immunofluorescence. In one case, only intracytoplasmic fluorescence was detected. Sixteen of 22 sera of patients with sarcoma gave positive reactions with antibody titers ranging from 40 to 160. Only 1 of 16 sera from patients with other neoplastic diseases and 1 serum of 18 normal sera gave positive results. The tumor antigen(s) present in this established cell line may provide an easy, standard source in the development of a clinical laboratory screening and monitoring assay for sarcoma tumors.

1 This work was supported in part by an institutional grant of the American Cancer Society (IN43L-02).

Received 10/31/72. Accepted 12/11/72.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1973 by the American Association for Cancer Research.